120IN - Adapting organisation and research infrastructures at Gustave Roussy for todays clinical research programmes

Date 29 September 2014
Event ESMO 2014
Session ESMO-ASCO: The evolution of the clinical trial landscape
Topics Bioethics, Legal, and Economic Issues
Translational Research
Presenter Alexander Eggermont
Citation Annals of Oncology (2014) 25 (suppl_4): iv41-iv42. 10.1093/annonc/mdu317
Authors A.M.M. Eggermont
  • -, Institut Gustave Roussy, 94805 - Villejuif/FR

Abstract

Body

Abstract:

Integration of basic-transltional-clinical research to create an interactive continuum, within one infrastuctural approach, has been the focus over the recent years at the Gustave Roussy Comprehensive Cancer Center. This continuum of cancer research activities is to articulate with cancer care and to advance with a key mission of the institute: to create tomorrows medicine. In order to achieve this a number of basic decisions had to be taken: 1) Adapt your clinical research infrastructures to the importance of creating a critical mass activity in early drug development. This was achieved by the creation of a department of drug development and treatment innovations harbouring all early clnical trial activities including the organizational nad monitoring aspects. 2) Develop and advance personalized cancer medicine by conducting clinical trials in this domain. This requested the creation of a molecular portrait platform that can deliver within in context of clinical requirements in terms of quality and speed. For this a whole floor of a 6000 M2 new translational research building was reserved and equipped, including bioinformatics. 3) Develop adequate infrastructural support in persons and platforms to participate in the revolution in immunotherapy of cancer. For this dedicated immunotherapists were recruted and an immunotherapy-monitoring platform was created. 4) Develop hi-tech platforms to accomodate on the one hand clinical trial requirements in personalized cancer medicine as indicated under points 1-2-3, as well as basic research platforms that a mutualized by all groups 5) Develop a model where a CCC will evolve into a Cancer Campus by creating and/or expanding large scale preclinical research facilities that will be a prerequisite to attract research branches of pharma, biotech, hi-tech and othe private companies to install themselves onto a cancer-center-surrounding biopark: cancer campus 6) Find the money All the above will provide the environment that will attrackt the best researchers and clinicians and research-clinicians to meet the expectations of society regarding advances to be made in cancer care, which is and remains the endgoal of all we do.

Disclosure:

The author has declared no conflicts of interest.